Search over 3,000 reports

    Jublia- Drug Insights, 2017

    Jublia- Drug Insights, 2017
    Date: Nov, 2017
    Type: Pharmaceutical Industry Report
    Pages: 35
    Geography: Global
    Delivery Timeline: 48 hours
    SKU: DIDI0059
    DelveInsight's pharmaceuticals report, " Jublia Drug Insights, 2017" highlights the Drug marketed details and the Global API Manufacturers details across the globe along with the location. The report covers the Global Market Assessment of the Jublia covering the historical global sales and also provides the Jublia sales estimation during the forecasted period (2017-2019). The report also covers the patents information and market exclusivity data, route of synthesis, market competition, and API manufacturers by country. In addition to this, the report also provides the SWOT analysis for Jublia and emerging therapies in this space.

    Scope

    A review of the Jublia, based on information derived from company and industry-specific sources
    Product details on the basis of MOA, target, dosage, route of administration, molecule type, strength, Chemical type and ATC Classification
    Coverage of the Drug Master Files and API Manufacturers by country
    Patent Expiry Timeline and Exclusivity Details
    Route of Synthesis of the API
    Forecasted Sales Figure from 2017-2019
    Market competition and emerging therapies
    SWOT Analysis
    DelveInsight Report Introduction
    Jublia- Overview
    Product Description
    Route of Synthesis
    Mechanism of Action
    Pharmacology
    Pharmacodynamics
    Pharmacokinetics
    Adverse Reactions
    Regulatory Milestones by Region
    Deals and Partnerships
    Product Details
    Jublia Sales Assessment
    Historical Sales
    Forecasted Sales
    Patent Details by Region
    Company Financials
    Market Competition
    Emerging Therapies*
    Drug 1
    Product Description
    Research and Development
    Product Development Activities
    SWOT Analysis
    Appendix
    Methodology
    Consulting Services
    About DelveInsight
    Contact Us
    Disclaimer
    Table 1: Jublia, Description
    Table 2: Jublia, Product Details
    Table 3: Jublia, Historical Sales (in million USD)
    Table 4: Jublia, Forecasted Sales from 2017-2019 (in million USD)
    Table 5: Jublia, Patent Details
    Table 6: Company, Overview
    Table 7: Jublia Major Competitors Jublia
    Table 8: Emerging Therapies
    Figure 1: Jublia, Historical Sales (in million USD)
    Figure 2: Jublia, Forecasted Sales from 2017-2019 (in million USD)
    Jublia
    Valeant Pharmaceuticals
    onychomycosis of the toenails due to Trichophyton rubrum and Trichophyton mentagrophyte
    Jublia Marketed Drugs Overview
    Jublia Market Assessment
    Jublia API Manufacturers/ Active Pharmaceutical Ingredients Manufacturers
    Jublia US DMF
    Jublia US Drug Master Files
    Jublia Active Substance Master File/ EUDMF
    Jublia Generic players
    Jublia Patent Expiration
    Jublia Patent Exclusivity
    Jublia API Manufacturers
    Jublia Global Forecasted Sales Figure
    Jublia API Route of Synthesis
    Jublia Market sales
    Jublia SWOT Analysis
    Jublia Pipeline
    • Single User License
      (20% Off)
      $1,000.00
      $800
    • Site License
      (30% Off)
      $2,000.00
      $1400
    • Global License
      (40% Off)
      $3,000.00
      $1800

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap